A Phase 4 interventional study of Insulin glargine, 300 U/ml and Insulin degludec, 100U/ml in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 7 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-14.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 11th largest by enrollment, is one of 2 that started in 2019, is one of 24 in phase 4, and was the 57th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 13th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2019, is one of 14 in phase 4, and was the 54th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
Secondary Objective:
To evaluate the glycemic control and variability parameters in each treatment group at Week 12 using Continuous Glucose Monitoring.
To evaluate the safety of insulin glargine 300 U/ml in comparison to insulin degludec 100 U/ml.
The duration of the study per participant was around 18 weeks: 1 or 2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
Drug: Insulin glargine, 300 U/ml · Drug: Background therapy: Rapid acting insulin analogs
Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
Drug: Insulin degludec, 100U/ml · Drug: Background therapy: Rapid acting insulin analogs
Drug page: Insulin Glargine
Pharmaceutical form: solution for injection in a prefilled pen Route of administration: SC injection
Also known as: Toujeo, HOE901-U300
Drug page: Insulin degludec
Pharmaceutical form: solution for injection in a prefilled pen Route of administration: SC injection
Also known as: Tresiba
Route of administration: SC injection
Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis
The Continuous Glucose Monitoring (CGM) system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained using analysis of covariance (ANCOVA) model on data obtained from the multiple imputations during Week 10 to Week 12.
Time frame: During Week 10 up to Week 12
Glucose Total Coefficient of Variation (CV%)
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated as ratio of standard deviation of glucose values to mean of glucose values. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
Time frame: During Week 10 up to Week 12
Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted LS means and SE were obtained using ANCOVA model on data obtained from the multiple imputations during Week 10 to Week 12.
Time frame: During Week 10 up to Week 12
Glucose Within-day CV% and Between-day CV%
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated within day and between days as ratio of standard deviation of glucose values to mean of glucose values. LS mean and SE were obtained from ANCOVA model including fixed categorical effects of treatment groups (TOUJEO, TRESIBA), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and as well as, the continuous fixed covariate of Baseline value.
Time frame: During Week 10 up to Week 12
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12
Change in HbA1c at Week 12 was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba), and the continuous fixed covariate of Baseline HbA1c value.
Time frame: Baseline, Week 12
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
Change in FPG was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba) and the randomization stratum of HbA1c at screening (\<8.0%, \>=8.0%) and the continuous fixed covariate of Baseline FPG value.
Time frame: Baseline, Week 12
Percentage of Time With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. "All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
Time frame: During Week 10 up to Week 12
Mean Hours Per Day With Glucose Level <70 Milligrams Per Deciliter (All Time and During the Night)
"All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. Mean hours per day with glucose level \<70 milligrams per deciliter during "all time" and only "during night" for the duration of Week 10 to Week 12 is reported in this outcome measure.
Time frame: During Week 10 up to Week 12
Percentage of Time With Glucose Level >180 Milligrams Per Deciliter
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
Time frame: During Week 10 up to Week 12
Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter
Mean hours per day with glucose level \>180 milligrams per deciliter for the duration of Week 10 to Week 12 is reported in this outcome measure.
Time frame: During Week 10 up to Week 12
Number of Participants With at Least One Hypoglycemic Event During the On-treatment Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 millimoles per liter (mmol/L) (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP.
Time frame: From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)
Number of Hypoglycemic Events Per Participant Year During the On-treatment Period
Number of hypoglycemia events (any, severe and documented) per participant-year of exposure were reported. Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 mmol/L (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP. Total participant years = The sum of the duration of exposure for all participants, expressed in participant years.
Time frame: From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days)
The study was conducted at 40 active sites in 7 countries. A total of 550 participants were screened between 09 October 2019 and 06 May 2021, of which 343 participants were enrolled and randomized by an interactive response technology (IRT) (1:1 ratio) to receive Toujeo or Tresiba. A total of 207 participants were screen failure mainly due to not meeting eligibility criteria.
| Milestone | Toujeo | Tresiba |
|---|---|---|
| Started | 172 | 171 |
| Completed | 164 | 167 |
| Not completed | 8 | 4 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Switch to insulin pump | 1 | 0 |
The Continuous Glucose Monitoring (CGM) system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained using analysis of covariance (ANCOVA) model on data obtained from the multiple imputations during Week 10 to Week 12.
| percentage of time | Toujeo | Tresiba |
|---|---|---|
| Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis | 52.74 ± 0.859 | 55.09 ± 0.893 |
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated as ratio of standard deviation of glucose values to mean of glucose values. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
| percentage of total CV | Toujeo | Tresiba |
|---|---|---|
| Glucose Total Coefficient of Variation (CV%) | 39.91 ± 0.360 | 41.22 ± 0.373 |
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted LS means and SE were obtained using ANCOVA model on data obtained from the multiple imputations during Week 10 to Week 12.
| percentage of time | Toujeo | Tresiba |
|---|---|---|
| Percentage of Time of Glucose Concentration Within the Target Range of >=70 to <=180 Milligrams Per Deciliter: Superiority Analysis | 52.74 ± 0.859 | 55.09 ± 0.893 |
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values, CV% was measure of glycemic variability across 20 days and calculated within day and between days as ratio of standard deviation of glucose values to mean of glucose values. LS mean and SE were obtained from ANCOVA model including fixed categorical effects of treatment groups (TOUJEO, TRESIBA), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and as well as, the continuous fixed covariate of Baseline value.
| percentage of CV | Toujeo | Tresiba |
|---|---|---|
| Within-day CV% | 33.48 ± 0.342 | 34.37 ± 0.351 |
| Between-day CV% | 17.23 ± 0.404 | 18.08 ± 0.415 |
Change in HbA1c at Week 12 was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba), and the continuous fixed covariate of Baseline HbA1c value.
| percentage of HbA1c | Toujeo | Tresiba |
|---|---|---|
| Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 12 | -0.75 ± 0.058 | -0.92 ± 0.057 |
Change in FPG was analyzed using an ANCOVA model including the fixed categorical effects of treatment groups (Toujeo, Tresiba) and the randomization stratum of HbA1c at screening (\<8.0%, \>=8.0%) and the continuous fixed covariate of Baseline FPG value.
| milligrams per deciliter | Toujeo | Tresiba |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 | -16.05 ± 5.455 | -34.55 ± 5.523 |
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. "All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
| percentage of time | Toujeo | Tresiba |
|---|---|---|
| All time | 5.55 ± 0.353 | 6.49 ± 0.362 |
| Night | 6.32 ± 0.511 | 6.26 ± 0.524 |
"All time" represent the time between 00.00 hour to 23.59 hours and "night" represent the time between 00.00 hour to 05.59 hours. Mean hours per day with glucose level \<70 milligrams per deciliter during "all time" and only "during night" for the duration of Week 10 to Week 12 is reported in this outcome measure.
| hours per day | Toujeo | Tresiba |
|---|---|---|
| All time | 1.33 ± 0.085 | 1.56 ± 0.087 |
| Night | 0.38 ± 0.031 | 0.38 ± 0.031 |
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. LS means and SE were obtained using ANCOVA model using fixed categorical effects of treatment groups (Toujeo, Tresiba), randomization stratum of screening HbA1c (\<8.0% versus \>=8.0%), and the continuous fixed covariate of Baseline value.
| percentage of time | Toujeo | Tresiba |
|---|---|---|
| Percentage of Time With Glucose Level >180 Milligrams Per Deciliter | 41.52 ± 0.975 | 38.31 ± 1.002 |
Mean hours per day with glucose level \>180 milligrams per deciliter for the duration of Week 10 to Week 12 is reported in this outcome measure.
| hours per day | Toujeo | Tresiba |
|---|---|---|
| Mean Hours Per Day With Glucose Level >180 Milligrams Per Deciliter | 9.96 ± 0.234 | 9.19 ± 0.240 |
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 millimoles per liter (mmol/L) (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP.
| Participants | Toujeo | Tresiba |
|---|---|---|
| Any hypoglycemia | 165 | 166 |
| Severe hypoglycemia | 8 | 10 |
| Documented symptomatic hypoglycemia | 136 | 134 |
Number of hypoglycemia events (any, severe and documented) per participant-year of exposure were reported. Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions, because the participant was not capable of helping self. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<3.9 mmol/L (\<70 milligrams per deciliter). On-treatment period was defined as the time from the first injection of IMP (included) up to 2 days after the last injection of IMP. Total participant years = The sum of the duration of exposure for all participants, expressed in participant years.
| events per participant-year | Toujeo | Tresiba |
|---|---|---|
| Any hypoglycemia | 109.4 | 114.9 |
| Severe hypoglycemia | 0.2 | 0.3 |
| Documented symptomatic hypoglycemia | 67.1 | 66.9 |
Collected over From the first injection of IMP up to 2 days after the last injection of IMP (i.e., up to 86 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Toujeo | 0/172 (0%) | 7/172 (4.1%) | 0/172 (0%) |
| Tresiba | 0/171 (0%) | 8/171 (4.7%) | 0/171 (0%) |
| Event | Toujeo | Tresiba |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/172 | 4/171 |
| Hypoglycaemic UnconsciousnessNervous system disorders | 4/172 | 2/171 |
| Hypoglycaemic SeizureNervous system disorders | 2/172 | 0/171 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 0/172 | 1/171 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/172 | 1/171 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/172 | 1/171 |
| Accidental OverdoseInjury, poisoning and procedural complications | 0/172 | 1/171 |
| Orthostatic IntoleranceNervous system disorders | 1/172 | 0/171 |
Analysis was performed on intent-to-treat (ITT) population which included all randomized participants (who signed the informed consent form and were allocated to a treatment group before the first investigational medicinal product \[IMP\] administration and recorded in the IRT database), irrespective of the treatment actually received and were analyzed according to the treatment group allocated by randomization.
| Age, Continuous(years) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Mean | 42.9 ± 13.53 | 42.8 ± 13.05 | 42.8 ± 13.28 |
| Sex: Female, Male(Participants) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Female | 86 | 74 | 160 |
| Male | 86 | 97 | 183 |
| Race and Ethnicity Not Collected(Participants) | Toujeo | Tresiba | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2019 to primary completion in Sep 2021, 23 months.
Results were first posted in Nov 2022, 1 year 1 month after primary completion.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine